Stock Market

Virax Biolabs Introduces Monkeypox Virus Antigen Rapid Test Kit – VRAX Stock Short Squeeze

VRAX STOCK UPDATE: [stock_market_widget type=”inline” template=”generic” assets=”VRAX” markup=”{name} ({symbol}) is trading at {price} ({change_pct}). {symbol} has the current dollar volume of {volume}, 52 weeks high of {52_week_high}, and 52 weeks low of {52_week_low} per share. There are currently {shares_outstanding} shares of {symbol} outstanding with the current market cap of {market_cap}. ” api=”yf”]

LONDON, Sept. 20, 2022 /PRNewswire/ — Virax Biolabs (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union. The test kits are for use in point of care settings and can help healthcare professionals accurately identify a monkeypox infection in people suspected of carrying the monkeypox virus with results typically available in 15 minutes. It also serves as a valuable initial screening test for individuals that have been exposed to monkeypox infected patients or a high-risk environment. The specialized diagnostic kits can be found by contacting the company’s sales representatives.

Short Interest90,153 shares
Short Interest Ratio0.35 Days to Cover
Short Interest % Float1.92%
Off-Exchange Short Volume59,886 shares – source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio51.34% – source: FINRA (inc. Dark Pool volume)

Last update: now

Time Since
Last Change
Timestamp (UTC)VRAX Short Shares Availability
1 hour ago2022-09-20 12:51:42.2230
1 hour ago2022-09-20 12:21:42.22350,000
2 hours ago2022-09-20 11:50:44.293100,000
3 days ago2022-09-17 02:20:49.333150,000

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button